Clinical Trial

Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2025 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are: 1. How does melatonin affect central macula thickness in CSCR? 2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR. Participants will: 1. Take melatonin or placebo twice a day for one month 2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests 3. Keep a diary of their symptoms
Trial Details
NCT Number NCT06809751
Lead Sponsor Mohsen Pourazizi
Conditions Central Serous Chorioretinopathy, Melatonin, Ocular Diseases, Visual Acuity, Macula Abnormality
Enrollment 48 participants
Start Date 2025-02-01
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-05